vykyvimote.wordpress.com
But the agreement, approved at a hastily arrangerdspecial meeting, is contingent on a satisfactoryh resolution regarding The Shipyard redevelopment project being reached between the city'as General Counsel's Office and , developer of The Shipyards. The contingency is based on concernsthat TriLegacy's problems with the city could affect ICS because the Spence family controls both companies. TriLegach and the city have been negotiating since April 16 to resolve a disagreement over how the compangyused $36.
5 million in city money at The Neither side has commented publicly on the procesas since the negotiations began, but according to correspondencse exchanged between the city and TriLegacyg in early April, the conflict centers on the two parties' interpretationx of the redevelopment agreement. In letteres to the city's Office of Genera l Counsel, TriLegacy lawyers contend that the redevelopmengt agreement allows the company to use the money as itsees fit, providec that at least $40 millionn is spent on "public by the end of the project.
City however, disagreed with the characterizatiojn and requested the company provide detailed records of the Rick Mullaney, general counsel for the apologized to the authority's board for not having finalized an agreemeny between TriLegacy and the city befor e the meeting, adding that he expected to have a settlementr in place within 48 hours. Greg Dawson, outside counsel for ICS from theEdwards & Cohen P.A. law firm in said he saw no need for any contingency relatedr to TheShipyards project, explaining that ICS and TriLegacy are separat operating companies and that ICS is financiallt healthy.
But he conceded that he would rathed see the lease agreement approved with the contingency than notat all. Dawsojn said time was of the essencebecause UPM-Kymmene, the Finnisnh company that will use much of the warehouse to store largd rolls of imported paper, had indicatedf it was growing weary of delays and was looking elsewhere. "They said they are explorint alternatives," Dawson said after the meeting. "Thet said they need to Port Authority Executive Director Rick Ferrihn told board membersthat ICS's 11-year historyh at the port gives him confidencs that the company will be able to meet its obligationas regarding the lease.
Martt Fiorentino, the board's president, said he believes the contingencgy tothe board's approval will be moot "We're close to being theres anyway," he said of the city'xs negotiations on The Shipyards, "or we wouldn'ty have moved forward."
Sunday, May 15, 2011
Friday, May 13, 2011
Osama Bin Laden's wives questioned by US officials, described as 'hostile' to ... - New York Daily News
http://www.teachingenglish.org.uk/users/kozanostra
New York Daily News | Osama Bin Laden's wives questioned by US officials, described as 'hostile' to ... New York Daily News The three women were all detained following the raid on the Al Qaeda leader's Pakistan hideout, which killed him and four others. They were reportedly "hostile" to the Americans, and the eldest of the group acted as spokeswoman. ... |
Wednesday, May 11, 2011
South China Quarry Landslide: 19 Dead, 3 Still Missing - Bernama
adamovaichive.blogspot.com
South China Quarry Landslide: 19 Dead, 3 Still Missing Bernama GUILIN, May 11 (Bernama) -- Nineteen workers have been confirmed dead while three others remain missing after a quarry was buried by landslide debris on Monday in south China's Guangxi Zhuang Autonomous Region, the local rescue headquarters said ... No traces of life after landslide hits south China quarry China landslide toll up to 14, eight missing: Xinhua 12 Dead, 10 Missing in S. China Quarry Landslide |
Sunday, May 8, 2011
Statehouse Insider: Budget work getting messy - The State Journal-Register
steinberg-virus.blogspot.com
Statehouse Insider: Budget work getting messy The State Journal-Register By Anonymous Remember that old saying about sausage and laws being two things you don't want to watch being made? It's beginning to look like you can add state budgets to that list. The big move in both the House and Senate this year is to return ... |
Friday, May 6, 2011
Wednesday, May 4, 2011
Benicia braces for possible park closures under state budget cuts - San Jose Mercury News
http://bestanca.com/actividades/2011/caminhada-vale-bestanca/
Benicia braces for possible park closures under state budget cuts San Jose Mercury News A possible state park closure list has not yet been released, but advocates say local residents and elected officials must prepare and take up the fight to keep the Benicia State Recreation Area and Benicia State Historic Park open. ... |
Sunday, May 1, 2011
Latest blockbuster for Merck: Sirna purchase - Puget Sound Business Journal (Seattle):
iwyqaxewun.wordpress.com
billion acquisition of made a big and like a rock thrown intoa pond, the deal has sent ripplews out in all directions. In the drug giant won a bidding contest to acquireSan Francisco-based Sirna for $13 a share, about twicew the price of the stock beforwe the companies announced the deal. For Merck, which is aggressivelh building its pipeline following the withdrawal of its blockbuster pain medicationj Vioxx fromthe market, the deal representx an effort to harness an innovative drug development platform it hopess will serve as an engine to produce new Merck Research Laboratories president Peter Kim has said the company believee RNAi could change how it discovers and develops and could become a new way to treat patients with unme t medical needs.
The technology could be particularly attractive in cancef therapy because it promises to target the activity of genesx that control cancer cells and destroh them without damagingnormal cells. For Sirna, the deal was a remarkablre turnin fortunes. Just four years ago, the companyh was running out of money and had a market capitalization ofabougt $5 million. But by the time Merck begann talking to Sirna about a possible collaboration todevelolp RNAi-based cancer drugs, it had rivalsd for Sirna's attention.
Merck was just one of four companies vyinb for a collaboration in Other companies were interested in working with Sirna possiblyu in diabetes and metabolic disease aswell -- and in relationshipsz that went beyond collaboration. "Those deals became pretty rich dealse in termsof cash," former Sirna CEO Howard who now heads San Carlos-based , told the Businessw Times at the time of the "At some point, two of the companies given the importance of the technology and the power of the technologty and how much Sirna has accomplished in the field, it woulr be a great investmenft to just buy Sirna Therapeutics." That led to a biddinyg contest.
Merck's opening bid was topped by an unidentifiedx rival who said it would paybetween $10 and $12 a according to regulatory filings. Mercok countered with its $13 a share bid to win the The biggest winner inthe deal, may not be shareholders of either company, but San Francisclo itself, which lured Sirna from its home in Colo. to Mission Bay. The acquisitiob puts one of the world's largest pharmaceutica companies at the heart ofthe city'ss effort to transform former industriapl wasteland into a thrivinvg center for life sciences.
It also puts the pharmaceutical giant'sd power behind Sirna, ensuringt that its still unproven technology will have the opportunity to reacb itsfull potential. Sirna is developing a new clasz of drugs that uses RNA interferencw orRNAi technology. RNAi is a natural, selective procesas for turning off RNAi is triggeredby so-called short interfering RNA or Typically, drugs work by binding with proteins that are the underlyingf cause of a specific disease. Sirna's technology, by contrast, prevent s the production of thedeleterious protein. Mercj had already been working in the area of RNAi throug h its collaborationwith .
The deal placed it at the forefront of a breakthrough technology that has the potential for changingh the way a wide range of diseasesare treated. It complementw Merck's 2001 acquisition of , which gave it tools to analyzegene expression. At the time of the Sirna had been pursuing a strategy of collaborating to develo therapeutics with partners around specificvdisease areas. The company had already entered into a collaboratiohn with Allergen to develop siRNA therapeutica for the wet formof age-related macular a leading cause of blindness in the The company also has a collaboration with to develoo siRNA compounds for respiratory disease.
Sirna has several other programs coveringh a broad range oftherapeutic areas.
billion acquisition of made a big and like a rock thrown intoa pond, the deal has sent ripplews out in all directions. In the drug giant won a bidding contest to acquireSan Francisco-based Sirna for $13 a share, about twicew the price of the stock beforwe the companies announced the deal. For Merck, which is aggressivelh building its pipeline following the withdrawal of its blockbuster pain medicationj Vioxx fromthe market, the deal representx an effort to harness an innovative drug development platform it hopess will serve as an engine to produce new Merck Research Laboratories president Peter Kim has said the company believee RNAi could change how it discovers and develops and could become a new way to treat patients with unme t medical needs.
The technology could be particularly attractive in cancef therapy because it promises to target the activity of genesx that control cancer cells and destroh them without damagingnormal cells. For Sirna, the deal was a remarkablre turnin fortunes. Just four years ago, the companyh was running out of money and had a market capitalization ofabougt $5 million. But by the time Merck begann talking to Sirna about a possible collaboration todevelolp RNAi-based cancer drugs, it had rivalsd for Sirna's attention.
Merck was just one of four companies vyinb for a collaboration in Other companies were interested in working with Sirna possiblyu in diabetes and metabolic disease aswell -- and in relationshipsz that went beyond collaboration. "Those deals became pretty rich dealse in termsof cash," former Sirna CEO Howard who now heads San Carlos-based , told the Businessw Times at the time of the "At some point, two of the companies given the importance of the technology and the power of the technologty and how much Sirna has accomplished in the field, it woulr be a great investmenft to just buy Sirna Therapeutics." That led to a biddinyg contest.
Merck's opening bid was topped by an unidentifiedx rival who said it would paybetween $10 and $12 a according to regulatory filings. Mercok countered with its $13 a share bid to win the The biggest winner inthe deal, may not be shareholders of either company, but San Francisclo itself, which lured Sirna from its home in Colo. to Mission Bay. The acquisitiob puts one of the world's largest pharmaceutica companies at the heart ofthe city'ss effort to transform former industriapl wasteland into a thrivinvg center for life sciences.
It also puts the pharmaceutical giant'sd power behind Sirna, ensuringt that its still unproven technology will have the opportunity to reacb itsfull potential. Sirna is developing a new clasz of drugs that uses RNA interferencw orRNAi technology. RNAi is a natural, selective procesas for turning off RNAi is triggeredby so-called short interfering RNA or Typically, drugs work by binding with proteins that are the underlyingf cause of a specific disease. Sirna's technology, by contrast, prevent s the production of thedeleterious protein. Mercj had already been working in the area of RNAi throug h its collaborationwith .
The deal placed it at the forefront of a breakthrough technology that has the potential for changingh the way a wide range of diseasesare treated. It complementw Merck's 2001 acquisition of , which gave it tools to analyzegene expression. At the time of the Sirna had been pursuing a strategy of collaborating to develo therapeutics with partners around specificvdisease areas. The company had already entered into a collaboratiohn with Allergen to develop siRNA therapeutica for the wet formof age-related macular a leading cause of blindness in the The company also has a collaboration with to develoo siRNA compounds for respiratory disease.
Sirna has several other programs coveringh a broad range oftherapeutic areas.
Subscribe to:
Posts (Atom)